Projections of Incidence, Prevalence and Mortality from Melanoma in Spain


Objective: The incidence and mortality rates for cutaneous melanoma (CM) have increased markedly in the last few years. As such, the aim of this study was to forecast their progression in Spain up until 2022. Design: A prospective epidemiological study using the Miamod technique. The primary data source was the mortality statistics released by the National Statistics Institute. Study selection: The MIAMOD method was used. Data extraction: Cases of death due to general and melanoma-related mortality in Spain between 1998 and 2007. Results: In men, the incidence is expected to increase from 11.85 (adjusted: 8.52) to 14.79 (adjusted: 9.43) per 100,000 inhabitants over the period 1998-2022. Similarly, the mortality is expected to increase slightly from 5.84 (adjusted: 4.12) to 7.19 (adjusted: 4.49) per 100,000 inhabitants, and the prevalence from 73.72 (adjusted: 52.31) to 95.46 (adjusted: 60.02) per 100,000 inhabitants over the same period. In women, the incidence is expected to increase from 3.79 (adjusted: 3.04) to 6.46 (adjusted: 4.21) per 100,000 inhabitants between 1998 and 2022, although this increase is not statistically significant. The mortality is expected to increase from 1.67 (adjusted: 1.24) to 2.98 (adjusted: 1.86) per 100,000 inhabitants, and the prevalence from 50.04 (adjusted: 44.54) to 84.81 per (adjusted: 56.18) 100,000 inhabitants over the same period. Conclusions: Primary and secondary prevention programs for this disease must be maintained.

Share and Cite:

M. Bernal, D. Souza, G. Gomez and F. Gomez, "Projections of Incidence, Prevalence and Mortality from Melanoma in Spain," Journal of Cosmetics, Dermatological Sciences and Applications, Vol. 3 No. 2A, 2013, pp. 1-6. doi: 10.4236/jcdsa.2013.32A001.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] D. M. Parkin, S. L. Whelan, J. Ferlay, L. Teppo and D. B. Thomas, “Melanoma in: Cancer in Five Continents,” No. 155, IARC Scientific Publication." \t "_blank
[2] Centro Nacional de Epidemiologia.
[3] Instituto Nacional de Estadistica (INE). hptt//
[4] G. De Angelis, R. de Angelis, L. Frova and A. Verdecchia, “MIAMOD: A Computer Package to Estimate Chronic Disease Morbidity Using Mortality and Survival Data,” Computer Methods and Programs in Biomedicine, Vol. 44, No. 2, 1994, pp. 99-107. doi:10.1016/0169-2607(94)90091-4
[5] W. Weibull, “A Statistical Distribution Function of Wide Applicability,” Journal of Applied Mechanics, Vol. 18, 1951, pp. 293-297.
[6] http://
[8] Joinpoint Program.
[9] N. Nasser, “UVB: Susceptibility in Malignant Melanoma,” Anais Brasileiros de Dermatologia, Vol. 85, No. 6, 2010, pp. 843-848. doi:10.1590/S0365-05962010000600010
[10] T. Shibata, A. Kokubu, M. Miyamoto, Y. Sasajima and N. Yamazaki, “Mutant IDH1 Confers an in Vivo Growth in a Melanoma Cell Line with BRAF Mutation,” American Journal of Pathology, Vol. 178, No. 3, 2011, pp. 1395-1402. doi:10.1016/j.ajpath.2010.12.011
[11] Nordpred, “A Software for Predicting Trends in Cancer Incidence”. http://www.kreftregis
[12] T. Dyba and T. Hakulinen, “Comparison of Different Approaches to Incidence Prediction Based on Simple Interpolation Techniques,” Statistics in Medicine, Vol. 19, No. 13, 2000, pp. 1741-1752. doi:10.1002/1097-0258(20000715)19:13<1741::AID-SIM496>3.0.CO;2-O
[14] M. P. Curado, B. Edwards, H. R. Shin, et al., “Cancer in Five Incidence,” No. 160, IARC Scientific Publication, Lyon, 2009.
[15] R. Marcos-Gragera, N. Vilar-Coromina, J. Galceran, J. Borràs, R. Clèries, J. Ribes, R. Gispert, A. Izquierdo and J. M. Borràs, “Rising Trends in Incidence of Cutaneous Malignant Melanoma and Their Future Projections in Catalonia, Spain: Increasing Impact or Future Epidemic?” Journal of the European Academy of Dermatology and Venereology, Vol. 24, No. 9, 2010, pp. 1083-1088.
[16] E. de Vries and J. W. Coebergh, “Cutaneous Malignant Melanoma in Europe,” European Journal of Cancer, Vol. 40, No. 16, 2004, pp. 2355-2366. doi:10.1016/j.ejca.2004.06.003
[17] A. Stang and K. H. J?ckel, “Declining Mortality Rates for Nonmelanoma Skin Cancers in West Germany, 1968-99,” British Journal of Dermatology, Vol. 150, No. 3, 2004, pp. 517-522.
[18] A. H. Olsen, D. M. Parkin and P. Sasieni, “Cancer Mortality in the United Kingdom: Projections to the Year 2025,” British Journal of Cancer, Vol. 99, No. 9, 2008, pp. 1549-1554. doi:10.1038/sj.bjc.6604710
[19] G. de Espaaa, “Registro de Cancer de Espana. Incidencia y Mortalidad por Cancer 2001-2005,” 2011. http://saludpublicaEspa?
[20] SEER.
[22] M. Pollan and G. Lopez-Abente, “Mortality Trends in Cutaneous Malignant Melanoma in Spain 1967-1986,” Cancer Epidemiology, Biomarkers & Prevention, Vol. 2, No. 6, 1993, pp. 545-550.
[23] S. F. Altekruse, C. L. Kosary, M. Krapcho, N. Neyman, R. Aminou, W. Waldron and B. K. Edwards, “SEER Cancer Statistics Review, 1975-2007,” 2010.
[24] A. V. Giblin and J. M. Thomas, “Incidence, Mortality and Survival in Cutaneous Melanoma,” Journal of Plastic, Reconstructive & Aesthetic Surgery, Vol. 60, No. 1, 2007, pp. 32-40. doi:10.1016/j.bjps.2006.05.008
[25] M. Makredes, S. K. Hui and A. B. Kimball, “Melanoma in Hong Kong between 1983 and 2002: A Decreasing Trend in Incidence Observed in a Complex Socio-Political and Economic Setting,” Melanoma Research, Vol. 20, No. 5, 2010, pp. 427-430.
[27] B. L. Diffey, “The Future Incidence of Cutaneous Melanoma within UK,” British Journal of Dermatology, Vol. 151, No. 4, 2004, pp. 868-872. doi:10.1111/j.1365-2133.2004.06216.x
[28] A. C. Geller, S. M. Swetter, K. Brooks, M. F. Demierre and A. L. Yaroch, “Screening, Early Detection, and Trends for Melanoma: Current Status (2000-2006) and Future Directions,” Journal of the American Academy of Dermatology, Vol. 57, No. 4, 2007, pp. 555-572. doi:10.1016/j.jaad.2007.06.032

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.